



Absci to Participate in the 36th Annual Piper Sandler Healthcare Conference

11/21/2024

VANCOUVER, Wash. and NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming 36th Annual Piper Sandler Healthcare Conference in New York, NY.

Absci's Founder & CEO Sean McClain is scheduled to participate in a panel discussion titled "The Promise of AI in Drug Development" on Thursday, December 5th at 2:00 p.m. Eastern Time.

Interested parties may contact their Piper Sandler representative to request registration details for this live event.

About Absci

[Absci](#) is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our [Integrated Drug Creation](#)™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed candidates to wet lab-validated candidates in as little as six weeks. Absci's headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit www.absci.com and follow us on LinkedIn ([@absci](#)), X (Twitter) ([@Abscibia](#)), and [YouTube](#).

Investor Contact

Alex Khan
VP, Finance & Investor Relations
investors@absci.com

Media Contact

press@absci.com